dexamethasone + azacytidine + pegaspargase + tislelizumab

This is a **combination regimen composed of four pharmacologically active agents**: dexamethasone, azacytidine, pegaspargase, and tislelizumab. - **Dexamethasone** is a synthetic corticosteroid with anti-inflammatory and immunosuppressant properties, commonly used as an adjunct in cancer therapy to control inflammation and manage chemotherapy-associated side effects. - **Azacytidine** is a cytidine nucleoside analog that functions as a DNA methyltransferase inhibitor and is used as an epigenetic modulator, primarily for the treatment of myelodysplastic syndromes and acute myeloid leukemia. - **Pegaspargase** is a pegylated form of the enzyme asparaginase that depletes circulating asparagine, an amino acid essential for the survival of certain leukemic cells, most notably in acute lymphoblastic leukemia. - **Tislelizumab** is a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), functioning as an immune checkpoint inhibitor to restore T-cell mediated antitumor immune response. This four-drug combination is **not an FDA-approved or widely recognized commercial regimen**; its use would be considered experimental and has not been established as a standard of care for any specific indication as of July 2025. Each component plays a distinct role—immunomodulation (dexamethasone), epigenetic modification (azacytidine), metabolic targeting (pegaspargase), and immune checkpoint blockade (tislelizumab)—suggesting potential use in highly refractory hematologic malignancies or solid tumors as part of experimental protocols.

Other names

tislelizumab-Peking University-extranodal NK/T-cell lymphomaDexamethasone, Azacytidine, Pegaspargase, Tislelizumab